ROIVANT SCIENCES LTD. (ROIV)
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration
JATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public Offering
Perma-Pipe anuncia el cierre de una línea de crédito global de hasta $139 millones